Navigating the evolving therapeutic landscape in M1 Prostate Cancer
Navigating the evolving therapeutic landscape in M1 Prostate Cancer. Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France. Disclosure. Participation to advisory boards/honorarium for: Amgen, Astellas, Astrazeneca, Bayer, Curevac, Essa, Janssen, MSD, Orion, Sanofi.
674 views • 35 slides